- Home
- CZNC vs PALI Comparison
CZNC vs PALI Comparison
Compare CZNC & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | PALI |
|---|---|---|
| Founded | 1864 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5M | 359.7M |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CZNC | PALI |
|---|---|---|
| Price | $20.70 | $2.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $23.50 | $11.29 |
| AVG Volume (30 Days) | 34.4K | ★ 2.6M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | 7.64 | ★ 97.06 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,057.50 | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $18.02 | $0.55 |
| 52 Week High | $24.12 | $2.86 |
Technical Indicators
Market Signals| Indicator | CZNC | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 55.24 |
| Support Level | $19.91 | $1.53 |
| Resistance Level | $20.63 | $2.15 |
| Average True Range (ATR) | 0.51 | 0.10 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 32.05 | 82.28 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.